Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced its participation in several ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44 th Annual J.P ...

COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Good morning. It’s an exciting week not only for biotech M&A, but also for my city (Chicago) as we gear up for our big game ...

Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies, today announced its attendance at ...

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and ...

Eli Lilly & Co. is in advanced talks to acquire Ventyx Biosciences Inc. for more than $1 billion to expand its work in ...

G&A Expense -- $1.9 million, down from $2.3 million mainly due to lower compensation and recruitment spending. Cash on ...

A new partnership to promote Swedish clinical trials has been launched, but concerns remain about a lack of patient voices ...

Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic ...

Riflessi to Deploy Digital Twins of Luxury Fashion Lines of Brunello Cucinelli, Gucci, Tom Ford, Kiton and Tommy Hilfiger ...